Clinical Trial Update: Effects of Miglustat Therapy on Infantile Type of Sandhoff and Taysachs Diseases (EMTISTD) [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating miglustat therapy for infantile GM2 gangliosidosis (Sandhoff and Tay-Sachs diseases) has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gm2 Gangliosidosis
• Sandhoff Disease
• Tay-sachs Disease

Drugs mentioned

• Miglustat (miglustat)

Snippet

Sponsor: Tehran University of Medical Sciences | Conditions: GM2 Gangliosidosis, Supportive Care | Phase 3 | Status: TERMINATED